###begin article-title 0
###xml 96 101 <span type="species:ncbi:9606">Human</span>
Genetic Epidemiology of Glioblastoma Multiforme: Confirmatory and New Findings from Analyses of Human Leukocyte Antigen Alleles and Motifs
###end article-title 0
###begin p 1
Conceived and designed the experiments: AMR YL RK MB JT. Performed the experiments: WS LH RN WS. Analyzed the data: WS AMR LH YL WS MB JT. Contributed reagents/materials/analysis tools: AMR RN RK MB JT. Wrote the paper: WS AMR LH YL RK JT. Reviewed the literature: JT AMR.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 148 153 148 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 158 163 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-C</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human leukocyte antigen (HLA) class I genes mediate cytotoxic T-lymphocyte responses and natural killer cell function. In a previous study, several HLA-B and HLA-C alleles and haplotypes were positively or negatively associated with the occurrence and prognosis of glioblastoma multiforme (GBM).
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 526 527 526 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 699 704 699 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 829 834 829 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 1086 1091 1086 1091 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 1154 1155 1154 1155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 422 430 <span type="species:ncbi:9606">patients</span>
As an extension of the Upper Midwest Health Study, we have performed HLA genotyping for 149 GBM patients and 149 healthy control subjects from a non-metropolitan population consisting almost exclusively of European Americans. Conditional logistic regression models did not reproduce the association of HLA-B*07 or the B*07-Cw*07 haplotype with GBM. Nonetheless, HLA-A*32, which has previously been shown to predispose GBM patients to a favorable prognosis, was negatively associated with occurrence of GBM (odds ratio = 0.41, p = 0.04 by univariate analysis). Other alleles (A*29, A*30, A*31 and A*33) within the A19 serology group to which A*32 belongs showed inconsistent trends. Sequencing-based HLA-A genotyping established that A*3201 was the single A*32 allele underlying the observed association. Additional evaluation of HLA-A promoter and exon 1 sequences did not detect any unexpected single nucleotide polymorphisms that could suggest differential allelic expression. Further analyses restricted to female GBM cases and controls revealed a second association with a specific HLA-B sequence motif corresponding to Bw4-80Ile (odds ratio = 2.71, p = 0.02).
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
HLA-A allelic product encoded by A*3201 is likely to be functionally important to GBM. The novel, sex-specific association will require further confirmation in other representative study populations.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 190 193 190 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Davis1">[1]</xref>
###xml 194 197 194 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Wen1">[7]</xref>
###xml 349 352 349 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Davis1">[1]</xref>
###xml 354 357 354 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Surawicz1">[2]</xref>
###xml 359 362 359 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Chen1">[8]</xref>
###xml 364 367 364 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-CBTRUS1">[9]</xref>
###xml 654 658 654 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Bondy1">[10]</xref>
###xml 331 334 <span type="species:ncbi:9606">men</span>
###xml 343 348 <span type="species:ncbi:9606">women</span>
Glioblastoma multiforme (GBM, also known as Grade IV glioma) is the most common and most severe form of primary brain cancer, with well-documented molecular heterogeneity and rapid fatality [1]-[7]. In the United States, age-adjusted GBM rates are 2.5 times higher in European Americans than in African Americans and 60% higher in men than in women [1], [2], [8], [9]. With varying degrees of certainty, additional factors associated with GBM range from occupational and dietary hazards to reproductive hormones, infectious agents, and variations in genes that regulate DNA repair, carcinogen metabolism, cell cycle, or inflammatory and immune responses [10]. Overall, genetic, developmental and environmental factors are all likely contributors to the etiology and pathogenesis of GBM.
###end p 9
###begin p 10
###xml 175 179 175 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Horton1">[11]</xref>
###xml 181 185 181 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Finn1">[12]</xref>
###xml 441 445 441 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Nitta1">[13]</xref>
###xml 446 450 446 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Tang1">[16]</xref>
###xml 517 521 517 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Burt1">[17]</xref>
###xml 522 526 522 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Hildesheim1">[19]</xref>
###xml 547 551 547 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Hildesheim2">[20]</xref>
###xml 552 556 552 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Zehbe1">[22]</xref>
###xml 672 676 672 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Apple1">[23]</xref>
###xml 677 681 677 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Zehbe2">[25]</xref>
###xml 38 43 <span type="species:ncbi:9606">human</span>
###xml 156 161 <span type="species:ncbi:9606">human</span>
Genes encoding the highly polymorphic human leukocyte antigens (HLA) are known to mediate inflammatory diseases, immune disorders, infectious diseases, and human malignancies [11], [12]. These and other clustered genes form the major histocompatibility complex (MHC) on the short arm of chromosome 6 (6p21.3) and most have dual roles in innate and adaptive immune responses. Multiple HLA alleles and haplotypes have been associated with GBM [13]-[16] as well as other malignancies, including nasopharyngeal carcinoma [17]-[19] and cervical cancer [20]-[22]. Some of these reported associations have been partially replicated and/or validated in studies of immune function [23]-[25], while most appear to be population- or study-specific findings with largely dubious pathogenetic implications.
###end p 10
###begin p 11
###xml 198 202 198 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Tang1">[16]</xref>
###xml 298 303 298 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
In previous work based on 155 GBM patients and 157 healthy control subjects recruited from the San Francisco Bay area, several HLA factors have been associated with GBM occurrence and its prognosis [16]. Our follow-up study in a different population now provides further evidence that at least one HLA-A allele known as A*3201 may well be a favorable allele that deserves further investigation.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
Overall characteristics of the study population
###end title 13
###begin p 14
###xml 52 56 52 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Ruder1">[26]</xref>
###xml 58 62 58 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Brenner1">[27]</xref>
###xml 115 122 115 122 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 115 122 115 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007157-t001"><bold>Table 1</bold></xref>
###xml 566 567 566 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 243 251 <span type="species:ncbi:9606">patients</span>
###xml 365 373 <span type="species:ncbi:9606">patients</span>
###xml 527 535 <span type="species:ncbi:9606">patients</span>
###xml 697 705 <span type="species:ncbi:9606">patients</span>
Nested within the Upper Midwest Health Study (UMHS) [26], [27], 149 GBM patients and 149 healthy control subjects (Table 1) were selected based on 1:1 matching for four criteria, i.e., ethnicity, sex, age and county of residence. As a result, patients and controls were highly comparable in ethnic background, age and sex ratio, although four African American (AA) patients had to be paired with European Americans (EA) controls. Body mass index, which was not used as a selection criterion, was also quite similar between GBM patients and healthy control subjects (p = 0.469). These characteristics formed the basis for conditional logistic regression analyses of HLA genotypes in the paired GBM patients and controls.
###end p 14
###begin title 15
###xml 49 57 <span type="species:ncbi:9606">patients</span>
Characteristics of glioblastoma multiforme (GBM) patients and healthy control subjects selected from the Upper Midwest Health Study.
###end title 15
###begin p 16
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
P values>/=0.75 are omitted (-); EA = European American, F = female, M = male, SD = standard deviation, SE = standard error of the mean.
###end p 16
###begin title 17
Analyses of HLA alleles and haplotypes
###end title 17
###begin p 18
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 58 59 58 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 65 66 65 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 92 95 92 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA</italic>
###xml 96 100 96 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DRB1</italic>
###xml 266 267 264 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 342 349 340 347 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 342 349 340 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007157-t002"><bold>Table 2</bold></xref>
###xml 563 564 561 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
PCR-based genotyping for three HLA class I genes (HLA-A, -B and -C) and one class II locus (HLA-DRB1) was successful for all 149 case-control pairs. Within each locus, the global distribution of common alleles (frequency>/=0.01 in any given population) was similar (p>0.50) between the UMHS population and another population studied earlier (Table 2), as were the patterns of pairwise linkage disequilibrium (LD) among alleles from different loci (data not shown). Minor differences were noted for a few individual alleles, including A*32, B*14, B*55, and Cw*08 (p</=0.025 by univariate Chi-square or Fisher exact tests).
###end p 18
###begin title 19
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 42 43 42 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 46 47 46 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DRB1</italic>
###xml 130 131 130 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 154 155 154 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
Distribution of relatively common HLA-A, -B, -C, and -DRB1 variants in similar case-control populations studied here (this study, N = 298) and elsewhere (N = 312).
###end title 19
###begin p 20
###xml 93 97 93 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Tang1">[16]</xref>
###xml 185 187 185 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2N</italic>
###xml 299 300 299 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Previously studied population consists of European Americans from the San Francisco Bay area [16]. Rare alleles at each locus are grouped together (others), with number of chromosomes (2N) used as the denominator in all tabulations. Between study populations, statistically significant differences (p</=0.025) are seen with A*32, B*14, B*55, and Cw*08.
###end p 20
###begin p 21
###xml 55 60 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-C</italic>
###xml 88 96 88 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 169 170 169 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 184 185 184 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 203 204 203 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 279 280 279 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 300 307 300 307 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 3</bold>
###xml 300 307 300 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007157-t003"><bold>Table 3</bold></xref>
###xml 323 324 323 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 515 519 515 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Nitta1">[13]</xref>
###xml 520 524 520 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Tang1">[16]</xref>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 354 362 <span type="species:ncbi:9606">patients</span>
GBM patients and healthy controls were compared for 11 HLA-A, 14 HLA-B, 10 HLA-C and 11 HLA-DRB1 alleles in a total of 46 univariate models. Three variants, i.e., A*32 (n = 29), B*14 (n = 11), and B*40 (n = 46), were found to be over-represented among the healthy control group (p = 0.030 to 0.054) (Table 3), while Cw*05 (n = 50) was more common in GBM patients (22.2%) than in controls (11.4%) (odds ratio = 2.21, 95% confidence interval = 1.17-4.17). In contrast, no other alleles highlighted in earlier studies [13]-[16] showed any appreciable trend for positive or negative associations with the occurrence of GBM. Further analyses of local and extended haplotypes in this study population also failed to detect any notable relationships.
###end p 21
###begin title 22
Univariate analyses of HLA variants showing clear trend for association with occurrence of glioblastoma multiforme (GBM) in the Upper Midwest Health Study.
###end title 22
###begin p 23
###xml 49 50 49 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 155 163 <span type="species:ncbi:9606">patients</span>
Numbers below each group correspond to n (%) and p values are based on maximum likelihood Chi-square test or Fisher exact test (for B*14 only) for 149 GBM patients and 149 healthy controls. OR = odds ratio, CI = confidence interval.
###end p 23
###begin p 24
###xml 80 81 80 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 245 246 245 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 365 366 365 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 391 396 391 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
Multivariable analyses dismissed B*14 and B*40 as independent factors (adjusted p = 0.070 and 0.118, respectively). In the reduced multivariable model, A*32 retained its negative association with GBM (adjusted OR = 0.39, 95% CI = 0.16-0.91, and p = 0.024), with Cw*05 being the only variant showing positive association (adjusted OR = 2.48, 95% CI = 1.24-4.97, and p = 0.011). Sequencing of HLA-A exons 2 to 4 revealed that A*3201 was the only A*32 allele in the study population. Similar sequencing strategy confirmed that Cw*0501 was the only allele representing Cw*05.
###end p 24
###begin title 25
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
Insights gained from HLA-A promoter and exon 1 sequences
###end title 25
###begin p 26
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 91 100 89 98 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1a</bold>
###xml 91 100 89 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007157-g001"><bold>Figure 1a</bold></xref>
###xml 288 297 286 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007157.s001">Figure S1</xref>
###xml 288 297 286 295 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0007157.s001">Figure S1</xref></bold>
###xml 389 398 387 396 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1b</bold>
###xml 389 398 387 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007157-g001"><bold>Figure 1b</bold></xref>
###xml 415 424 413 422 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rs2230954</underline>
###xml 737 742 735 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 752 761 750 759 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1b</bold>
###xml 752 761 750 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007157-g001"><bold>Figure 1b</bold></xref>
###xml 789 798 787 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007157.s002">Figure S2</xref>
###xml 789 798 787 796 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0007157.s002">Figure S2</xref></bold>
###xml 906 910 904 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-McKenzie1">[28]</xref>
###xml 330 338 <span type="species:ncbi:9606">patients</span>
Selective sequencing of a 1000-bp fragment of HLA-A detected 51 SNPs at frequency >/=0.02 (Figure 1a); five had no known reference sequence (rs) number in the dbSNP database (version 126). Strong pairwise LD among some SNPs produced four apparent haplotype blocks, each having 3-23 SNPs (Figure S1). Regardless of DNA source (GBM patients or control subjects), A*3201 had six unique SNPs (Figure 1b), one of which (rs2230954) is nonsynonymous (Ser to Leu substitution) in the first exon. The other five (rs9260090, rs9260100, rs9260102, rs9260105 and rs2735113) are around the core promoter sequences, without any known or predictable functional attributes. DNA sequencing also allowed the assembly of homozygous sequences for 10 common HLA-A alleles (Figure 1b). A neighbor-joining tree (Figure S2) revealed topologies that were identical to known taxonomic hierarchy for their entire open reading frames [28].
###end p 26
###begin title 27
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
DNA polymorphisms within HLA-A promoter and exon 1 sequences.
###end title 27
###begin p 28
###xml 447 457 447 457 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">underlined</underline>
###xml 512 513 512 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 609 619 609 619 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">underlined</underline>
A 1000-bp region (Panel a) has been sequenced for select population samples. Upper case letters are cDNA sequences (part of the open reading frame); the translation start codon (ATG) is indicated by a horizontal arrow. STR denotes a short tandem repeat sequence that has either three or four AAC repeats. Five transcription factor-bindings sites (TFBS) are also indicated. Within this fragment, 69 single nucleotide polymorphisms (SNPs) (bold and underlined) have already been reported in the literature. Those (n = 19) not confirmed in this work are shaded grey. The five novel SNPs are designated as "New" (underlined nucleotides below vertical lines). The SNPs unique to A*3201 are marked by vertical arrows before their respective reference sequence (rs) numbers (from dbSNP database, version 126). In panel b, 53 informative SNPs (minor allele frequency >/=0.02) are linked to 11 HLA alleles found in homozygous state.
###end p 28
###begin title 29
Analyses of HLA class I sequence motifs
###end title 29
###begin p 30
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 7 9 7 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-B</italic>
###xml 15 17 15 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;C</italic>
###xml 237 242 237 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 344 345 344 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 356 363 356 363 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 4</bold>
###xml 356 363 356 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007157-t004"><bold>Table 4</bold></xref>
###xml 563 567 563 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Schreuder1">[29]</xref>
###xml 736 737 736 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 911 916 911 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 1010 1011 1010 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1031 1036 1031 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 1211 1212 1211 1212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 788 796 <span type="species:ncbi:9606">patients</span>
HLA-A, -B, and -C sequence motifs were defined by 43, 66, and 28 specific probes in the respective SSO assays. Most (81% to 89%) of them had enough inter-individual variations to be suitable for comparative analyses. The presence of the HLA-A motif defined by SSO probe 34 was negatively associated with GBM (OR = 0.50, 95% CI = 0.27-0.91, and p = 0.024) (Table 4). Common allele groups known to carry this motif include A*23, A*29, A*31, A*32 and A*33 (A*74 was not detected). With the exception of A*23, these allele groups all belong to the A19 serology group [29]. However, individuals whose DNA bound to SSO probe 34 in the absence of A*32 (A*3201) were no less likely to be cases than controls (OR = 0.59, 95% CI = 0.27-1.29, and p = 0.183), because modest trends seen with A*23 (8 patients versus 4 controls), A*31 (6 versus 4) and A*33 (3 versus 0) was reversed by A*29 (6 versus 9). Likewise, a common HLA-B motif defined by SSO probe 62 had a positive association (OR = 1.87, 95% CI = 1.13-3.10, and p = 0.015). Multiple HLA-B alleles (e.g., B*14, B*15, B*35, B*44, B*45, B*49, B*50, B*51, B*53, and B*57) are known to have this motif, but none of these alleles were individually associated with GBM (p>0.15 in all tests).
###end p 30
###begin title 31
###xml 149 150 149 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 199 207 <span type="species:ncbi:9606">patients</span>
Individual HLA class I sequence motifs associated with the occurrence of glioblasotma multiforme (GBM) in the Upper Midwest Health Study population (N = 298 subjects) or in the female subset (61 GBM patients and 61 healthy controls).
###end title 31
###begin p 32
###xml 121 126 121 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 190 191 190 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 191 192 191 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 205 206 205 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
As described in the text, HLA motifs are defined by individual sequence-specific oligonucleotide (SSO) probes, including HLA-B probes 30 and 34 that are in exclusive linkage disequilibrium (r2 = 1.0). The p values correspond to maximum likelihood estimates. OR = odds ratio, CI = confidence interval.
###end p 32
###begin p 33
###xml 167 174 167 174 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 4</bold>
###xml 167 174 167 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007157-t004"><bold>Table 4</bold></xref>
###xml 181 186 181 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 292 293 292 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 382 387 382 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 476 477 476 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 529 530 529 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 530 531 530 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 759 764 759 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 769 774 769 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 835 836 835 836 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 847 854 845 852 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 4</bold>
###xml 847 854 845 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007157-t004"><bold>Table 4</bold></xref>
Despite reduced statistical power, separate analyses of males and females revealed three more sequence motifs that appeared to be associated with GBM in females only (Table 4). The HLA-A sequence motif defined by SSO probe 42 showed a negative association (OR = 0.35, 95% CI = 0.15-0.83, and p = 0.017). Relatively common alleles with this motif include A*01, A*11, A*25, and A*26. HLA-B probes 30 and 34 had identical positive association (OR = 2.71, 95% CI = 1.14-6.46, and p = 0.024) because they were in exclusive (100%) LD (r2 = 1.0). Probe 34 corresponds to a subset of alleles having the Bw4 serological specificity, including B*15 (B*1510 and B*1517), B*39, B*49, B*51, B*53, and B*57. Multivariable analyses supported the independent associations of HLA-A and HLA-B motifs captured by probes 42 and 34, respectively (adjusted p</=0.017) (Table 4).
###end p 33
###begin p 34
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 227 232 227 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 384 389 384 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 406 411 406 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 451 456 451 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 525 530 525 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
Among the specific sequence motifs of interest, HLA-A probes 34 and 42 corresponds to four codons, 149-GCG, 151-CGT, 152-GTG and 153-GCG, and three codons, 161-SAG (where S is either G or C), 163-CGG and 165-GTG, respectively. HLA-B probe 30 detects four codons (75-CGA, 77-AAC, 78-CTG and 80-ATC), which have partial overlap with three codons (80-ATC, 81-GCG and 83-CGC) detected by HLA-B probe 34. Thus, HLA-B probes 30 and 34 share specificity for HLA-B codon 80-ATC (AUC in RNA, for Ile). Four more codons defined by the HLA-B probe 62 are 161-GAG (for Glu), 162-GGC (Gly), 163-CTG (Leu) and 164-TGC (Cys).
###end p 34
###begin title 35
###xml 50 55 <span type="species:ncbi:9606">human</span>
Genotypes of two SNPs with broad implications for human malignancies
###end title 35
###begin p 36
###xml 281 282 281 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 440 444 428 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Rafnar1">[30]</xref>
###xml 679 680 667 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 749 753 737 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Rafnar1">[30]</xref>
Consistent with results from the CEPH DNA samples analyzed by the International HapMap Project, SNPs rs401681 and rs2736098 in our study population had the minor allele as T and A, respectively. The frequency of rs401681[T] was 0.409 in healthy controls versus 0.440 in GBM cases (p>0.65). The rs401681[C] allele has been positively associated with multiple cancers (OR approximately1.2) but negatively associated with melanoma (OR = 0.88) [30]. Here, rs401681[C] was slightly less frequent in GBM cases than healthy controls (OR = 0.88 in test of allele frequency). For SNP rs2736098, the frequency of its minor allele A was 0.338 in healthy controls versus 0.288 in GBM cases (p>0.35), in contrast with its positive association with other cancers [30]. Overall, none of the differences in SNP alleles and genotypes (diplotypes) was close to statistical significance.
###end p 36
###begin title 37
Discussion
###end title 37
###begin p 38
###xml 193 197 193 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Tang1">[16]</xref>
###xml 598 603 598 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 608 613 608 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 769 770 769 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1024 1028 1018 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Ruder1">[26]</xref>
###xml 1030 1034 1024 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Ruder2">[31]</xref>
###xml 1221 1226 1215 1220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 1231 1236 1225 1230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-C</italic>
###xml 1289 1296 1283 1290 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 1289 1296 1283 1290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007157-t002"><bold>Table 2</bold></xref>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
In several ways, our study of GBM patients and healthy controls from the Upper Midwest Health Study (UMHS) refined and extended findings based on another cohort from the San Francisco Bay area [16]. First, most HLA factors (e.g., B*07, B*13, and Cw*01) revealed by the previous study could not be confirmed here, so their role in the origins of GBM, if any, is unlikely to be generalizable. Second, HLA-A*32 (A*3201) was the only allele that was favorable in both the San Francisco population (prolonged survival) and the Midwest population (protection from disease). Third, specific motifs in the HLA-A and HLA-B open reading frames appeared to be prominent factors in the Midwest cohort, especially in females. Statistically, age was the most significant difference (p<0.0001) between the San Francisco population (mean+/-standard deviation = 58+/-12) and the Midwest population (52+/-13), which might have contributed to inconsistent findings from these cohorts. Environmental factors, including those related to farming [26], [31], could further distinguish the Midwest cohort from the San Francisco cohort. Minor genetic heterogeneity can also offer some alternative explanations, because the frequencies of several HLA-B and HLA-C alleles differed between the two study populations (Table 2). Overall, discordant observations were apparent between the two cohorts despite their close similarity in ethnic background and sample size (statistical power), suggesting that other aspects of study design and population characteristics can be critical to epidemiological analyses.
###end p 38
###begin p 39
###xml 143 147 143 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Tang1">[16]</xref>
###xml 417 422 417 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 623 630 623 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KIR3DS1</italic>
###xml 635 642 635 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KIR3DL1</italic>
###xml 807 811 807 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Bashirova1">[32]</xref>
###xml 812 816 812 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Kulkarni1">[34]</xref>
###xml 867 871 867 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Tang1">[16]</xref>
###xml 930 938 930 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 975 979 975 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Machulla1">[15]</xref>
###xml 981 985 981 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Guerini1">[35]</xref>
Aside from the question about relative impact of specific HLA alleles or motifs on GBM in European Americans, our study here and previous work [16] both indicated that the association signals primarily came from the HLA class I region, which, if real, would imply the involvement of cytotoxic T-lymphocyte (CTL) and/or natural killer (NK) cell responses. In that regard, the Bw4 sequence motif (Bw4-80Ile, defined by HLA-B probe 34) associated with increased risk for GBM in females is of particular interest, due to its direct role in NK cell activities. Evaluation of two killer immunoglobulin-like receptor (KIR) genes, KIR3DS1 and KIR3DL1, could shed further light on the Bw4 association because these receptors directly or indirectly interact with the Bw4 motif to activate or inhibit NK cell function [32]-[34]. Meanwhile, analyses presented here and elsewhere [16] did not provide any corroboration of positive findings on HLA-DRB1 genotypes reported in small cohorts [15], [35]. Therefore, HLA class II alleles that dictate T-helper cell function lacked appreciable impact on GBM.
###end p 39
###begin p 40
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Finn1">[12]</xref>
###xml 180 185 180 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 187 189 187 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-B</italic>
###xml 195 197 195 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;C</italic>
###xml 199 203 199 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Lampson1">[36]</xref>
###xml 260 265 260 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-E</italic>
###xml 270 275 270 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-G</italic>
###xml 359 363 359 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Wiendl1">[37]</xref>
###xml 364 368 364 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Mittelbronn1">[39]</xref>
###xml 479 482 479 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Wen1">[7]</xref>
###xml 573 577 573 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Ueda1">[40]</xref>
###xml 650 654 650 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Tang2">[41]</xref>
###xml 783 787 783 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Okano1">[42]</xref>
###xml 788 792 788 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Shimato1">[44]</xref>
###xml 909 913 909 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Debinski1">[45]</xref>
###xml 914 918 914 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Yan1">[49]</xref>
###xml 1061 1065 1061 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Cao1">[50]</xref>
###xml 1067 1071 1067 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Maiers1">[51]</xref>
###xml 641 649 <span type="species:ncbi:9606">patients</span>
###xml 920 928 <span type="species:ncbi:9606">Patients</span>
###xml 1098 1106 <span type="species:ncbi:9606">patients</span>
The importance of HLA class I molecules to cancer immunology has been well recognized in experimental studies [12]. In brain cancer, low expression of classical HLA class I genes (HLA-A, -B, and -C) [36] coupled with up-regulation of nonclassical genes (e.g., HLA-E and HLA-G) likely contributes to immune escape by tumor cells with various somatic mutations [37]-[39]. On the other hand, a study of long-term survivors of anaplastic astrocytoma, which is closely related to GBM [7], has suggested that protective CTLs can effectively respond to glioma-associated antigens [40]. CTLs have indeed been detected in the peripheral blood of GBM patients [41] and antigenic epitopes derived from the alpha 2 chain of interleukin-13 receptor can be presented by HLA-A*02 (A*0201) and A*24 [42]-[44]. It remains to be seen if HLA-A*3201 is advantageous in presenting oncogenic antigens commonly seen in glioma cells [45]-[49]. Patients of African ancestry can be particularly informative as HLA-A alleles in the A19 serology group are most common in African Americans [50], [51]. Epidemiological study of patients with other major forms of brain cancer (e.g., anaplastic astrocytoma) should also help identify favorable HLA factors, which can lead to critical information about the underlying protective mechanisms.
###end p 40
###begin p 41
###xml 190 194 190 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Hughes1">[52]</xref>
###xml 326 330 326 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Goymer1">[53]</xref>
###xml 614 619 614 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 812 817 812 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 164 169 <span type="species:ncbi:9606">human</span>
HLA allelic diversity is earmarked by the dominance of nonsynonymous SNPs in the open reading frames, often as a consequence of balancing selection by a variety of human infectious diseases [52]. Such allelic diversity may be equally advantageous in the battle with cancerous cells that frequently switch antigenic repertoire [53]. Thus, in addition to examining the A*3201 open reading frame using routine HLA typing methods, we also partially surveyed regulatory sequences because allele-specific immune surveillance can further depend on allelic expression profile. Our work did reveal five SNP variants in the HLA-A promoter region that are likely specific to the A*3201 allele, but none of these is within known transcription factor-binding sites. Expanded analyses of other non-coding sequences around the HLA-A locus may help determine whether regulatory sequences beyond the promoter region can separate favorable from unfavorable or neutral alleles, especially when closely related alleles (e.g., A*3201 and others in the A19 serology group) differ in their impact on disease.
###end p 41
###begin p 42
###xml 475 479 475 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Rafnar1">[30]</xref>
###xml 566 570 566 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Shete1">[54]</xref>
###xml 572 576 572 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Wrensch2">[55]</xref>
###xml 707 714 707 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLPTM1L</italic>
###xml 456 461 <span type="species:ncbi:9606">human</span>
In other brain tumor studies that have dealt with candidate genes outside the HLA system (reviewed in ref. 10), the magnitudes of genetic associations (usually with SNP genotypes) have generally been modest. Further evidence from SNP-based genome-wide association studies has been equally unremarkable (less than 2-fold difference), including the recent implication of two SNPs (rs401681 and rs2736098) consistently but weakly associated with a variety of human malignancies [30], as well as other SNP genotypes detected in genome-wide association studies of glioma [54], [55]. Indeed, our analyses of rs401681 and rs2736098 produced only minimal evidence that allele C of the intronic SNP rs401681 (at the CLPTM1L locus) is probably unfavorable in brain cancer.
###end p 42
###begin p 43
###xml 60 64 60 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Tang1">[16]</xref>
###xml 467 471 467 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Schreuder1">[29]</xref>
###xml 473 477 473 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Cao1">[50]</xref>
###xml 479 483 479 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Middleton1">[56]</xref>
###xml 916 920 916 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Bondy1">[10]</xref>
###xml 1166 1169 1166 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Wrensch1">[4]</xref>
###xml 1171 1174 1171 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Wen1">[7]</xref>
###xml 1329 1332 1329 1332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Wen1">[7]</xref>
In summary, case-control studies described here and earlier [16] have yielded clues to potential involvement of HLA class I alleles and motifs in GBM. The findings are still difficult to interpret because none of them can be immediately related to other reports on solid tumors. Of note, HLA-A*3201 (A19 or A32 by serology) is a relatively infrequent allele, with an overall carriage ("phenotype") frequency less than 10% (allele frequency <0.05) in most populations [29], [50], [56]. Lack of information about this allele is not surprising, because even studies of adequate sample size (i.e., hundreds to thousands of cases and controls) can have limited statistical power if the association is weak or obscured by other factors. Bw4-80Ile, on the other hand, is a common variant; hypothesis about Bw4-80Ile can be readily tested. Large collaborative efforts, as promoted by the Brain Tumor Epidemiology Consortium [10], are expected to expedite confirmatory studies of HLA alleles and motifs in other well-defined cohorts, especially those of diverse ethnic backgrounds as well as wide geographic coverage. Recognition of GBM as a molecularly heterogeneous cancer [4], [7] also calls for the separate analyses of primary and secondary glioblastoma, as the latter is closely related to anaplastic astrocytoma (Grade III glioma) [7].
###end p 43
###begin title 44
Materials and Methods
###end title 44
###begin title 45
Study population
###end title 45
###begin p 46
###xml 64 68 64 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Ruder1">[26]</xref>
###xml 70 74 70 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Brenner1">[27]</xref>
###xml 852 859 850 857 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 852 859 850 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007157-t001"><bold>Table 1</bold></xref>
###xml 98 106 <span type="species:ncbi:9606">patients</span>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
###xml 565 573 <span type="species:ncbi:9606">patients</span>
###xml 821 829 <span type="species:ncbi:9606">patients</span>
###xml 947 952 <span type="species:ncbi:9606">Human</span>
###xml 991 996 <span type="species:ncbi:9606">human</span>
###xml 1011 1019 <span type="species:ncbi:9606">patients</span>
We studied unrelated subjects in the Upper Midwest Health Study [26], [27], which enrolled cancer patients and frequency-matched, population-based controls from non-metropolitan areas in four Midwest states (Iowa, Michigan, Minnesota and Wisconsin). All patients with glioblastoma multiforme (GBM = Grade IV glioma, as classified by the World Health Organization) were included if they were 18 years or older at time of GBM diagnosis and blood sampling. Healthy control subjects drawn from this study had no self-reported cancer of any type and were matched to GBM patients at a 1:1 ratio by sex, state of residence and at least two of three additional criteria, i.e., age (+/-3 yr), race/ethnicity (self-identified), and county of residence (or adjacent county). The final study population consisted of 149 pairs of GBM patients and healthy controls (Table 1). The original research and this substudy conformed to the US Department of Health and Human Services guidelines for protection of human subjects. All patients and healthy controls provided written informed consent. The procedures for obtaining written informed consent, blood sample, clinical information, data management and data analysis were approved by institutional review board (IRB) at the National Institute for Occupational Safety and Health (NIOSH, Protocol HSRB 94-DSHEFS-08). Work related to this substudy was further approved by IRBs at NIOSH and University of Alabama at Birmingham (Protocol X071005007).
###end p 46
###begin title 47
HLA Genotyping
###end title 47
###begin p 48
###xml 167 171 167 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Brenner1">[27]</xref>
###xml 232 237 232 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 239 244 239 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-B</italic>
###xml 250 255 250 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-C</italic>
###xml 309 317 309 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 420 424 420 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Shao1">[57]</xref>
###xml 426 430 426 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Tang3">[58]</xref>
###xml 1116 1124 1116 1124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 1339 1340 1339 1340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Genomic DNA samples, prepared from whole blood either using the QIAamp blood kit (QIAGEN Inc., Chatsworth, Calif., USA) or by sodium-perchlorate chloroform extraction [27], were used for molecular typing of three HLA class I genes (HLA-A, HLA-B, and HLA-C), along with the most polymorphic HLA class II gene, HLA-DRB1. Genotyping relied on a combination of PCR-based techniques commonly used in population-based studies [57], [58]. Briefly, alleles (4-digit designations) and allele groups (2-digit designations) from the three HLA class I genes were first amplified by locus-specific primer mixes and then classified after automated hybridization to sequence-specific oligonucleotide (SSO) probes (Innogenetics, Alpharetta, Georgia, USA). Ambiguous HLA class I genotypes were resolved by sequencing-based typing (SBT), which covered three exons (2-4) in six sequencing reactions (three forward and three reverse) (Abbott Molecular, Inc., Des Plaines, Illinois, USA). Capillary electrophoresis and allele assignments in SBT were done using the ABI 3130xl DNA Analyzer (Applied Biosystems, Foster City, Calif., USA). HLA-DRB1 alleles in the HLA class II region were directly resolved by sequencing exon 2 in three reactions (forward, reverse, and codon 86) (Abbott Molecular, Inc.). For quality control purposes, randomly selected samples (n = 39, or 13% of the total) were genotyped in duplicate.
###end p 48
###begin title 49
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
Confirmatory sequencing of HLA-A promoter and exon 1 sequences
###end title 49
###begin p 50
###xml 78 87 78 87 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1a</bold>
###xml 78 87 78 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007157-g001"><bold>Figure 1a</bold></xref>
###xml 272 276 272 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-LHaridon1">[59]</xref>
###xml 277 281 277 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Girdlestone1">[61]</xref>
###xml 749 758 749 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007157.s002">Figure S2</xref>
###xml 749 758 749 758 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="supplementary-material" rid="pone.0007157.s002">Figure S2</xref></bold>
###xml 874 878 874 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-McKenzie1">[28]</xref>
To enhance the interpretation of findings on HLA-A alleles, a 1000-bp region (Figure 1a) not targeted in routine genotyping was sequenced using a commercial, high-throughput platform (Polymorphic DNA Technologies, Alameda, Calif., USA). The fragment has the core promoter [59]-[61] and exon 1 sequences, with >60 single nucleotide polymorphisms (SNPs). Eight PCR primers and eight internal sequencing primers (sequences available from JT upon request) were used for bidirectional sequencing in subjects who carried homozygous genotypes or common alleles of interest. Individual SNP genotypes were analyzed for pairwise linkage disequilibrium (LD) using the HaploView program (). Homozygous sequences were also tested for phylogenetic relationships (Figure S2) that could be directly compared with known taxonomic hierarchy for protein-coding sequences (open reading frames) [28].
###end p 50
###begin title 51
###xml 60 65 <span type="species:ncbi:9606">human</span>
Selective genoyping of two SNPs with broad implications for human malignancies
###end title 51
###begin p 52
###xml 108 112 108 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Rafnar1">[30]</xref>
###xml 94 99 <span type="species:ncbi:9606">human</span>
For exploratory analyses, two SNPs (rs401681 and rs2736098) recently associated with multiple human cancers [30] were typed for all GBM cases and healthy controls using pre-designed TaqMan (5' nuclease) assays (assay-on demand IDs C_1150767_20 and C_26414916_20, respectively) (Applied Biosystems, Foster City, CA). Based on procedures recommended by the manufacturer, the SNP assays were run in 6-microL PCR reactions in 96-well plates, with each reaction having 10 ng total genomic DNA mixed with 2x TaqMan Universal PCR Master Mix (Applied Biosystems). Allelic discrimination relied on end-point fluorescence intensity after 35 cycles of PCR (denaturing at 95degreesC for 15 sec and annealing/extending at 60degreesC for 60 sec) in an ABI 7500 FAST system (Applied Biosystems). Each plate had four wells for negative controls (no template DNA added) and 3% of all DNA samples were tested in random duplicates for quality control.
###end p 52
###begin title 53
Statistical analyses
###end title 53
###begin p 54
###xml 232 236 232 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007157-Tang1">[16]</xref>
Statistical Analysis Software (SAS), version 9.2 (SAS Institute, Cary, North Carolina, USA) was used for all descriptive statistics and comparative analyses. Serial analytical strategies were similar to those reported in prior work [16], with a starting focus on 2-digit allele groups (often equivalent to serological specificities) and linkage disequilibrium (LD) between HLA factors. Only common variants found in at least 10 individuals (approximately3.4% of the study population) were formally tested. In all hypothesis testing, a nominal P value</=0.05 was considered statistically significant. Multivariable and conditional logistic regression models with backward or step-wise selection procedure were used to generate the parsimonious models with all independent factors (adjusted multivariable P value</=0.05). Novel associations were reported as such if the univariate P value was <0.05 in conditional logistic regression models. As homozygosity with any given HLA allele or motif (defined by individual SSO probes) was rare, statistical models only tested dominant effects. Analyses of individual SNP genotypes were modeled for recessive effects (homozygosity or two copies of the minor allele), dominant effects (homo- and heterozygosity combined), and additive effects (0, 1 and 2 copies of the minor allele). Estimates of odds ratio (OR) and 95% confidence interval (CI) were the main summary statistics from these analyses.
###end p 54
###begin title 55
Supporting Information
###end title 55
###begin p 56
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
###xml 253 261 251 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007157-g001">Figure 1</xref>
Patterns of linkage disequilibrium (LD) among informative SNPs within HLA-A promoter and exon 1 sequences. Novel SNPs without the official reference sequence (rs) numbers are designated as "New." Among the 51 SNPs with minor allele frequencies >/=0.02 (Figure 1), one (rs9260109) is excluded from this analysis because of three different alleles (i.e., not dimorphic) at this site. Strong pairwise LD (shown in red) leads to the identification of four haplotype blocks (framed), which consist of 13, 23, 6 and 3 SNPs, respectively.
###end p 56
###begin p 57
(0.27 MB DOC)
###end p 57
###begin p 58
Click here for additional data file.
###end p 58
###begin p 59
###xml 69 74 69 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-A</italic>
Neighbor-joining tree illustrating the phylogenetic relationships of HLA-A promoter and exon 1 sequences representing 11 alleles found in homozygous state. Two alleles (A*260101 and A*320101) have the full, 6-digit designations. Scale of genetic distance is shown at the bottom.
###end p 59
###begin p 60
(0.05 MB DOC)
###end p 60
###begin p 61
Click here for additional data file.
###end p 61
###begin p 62
This study benefited from the Brain SPORE (Specialized Programs of Research Excellence) project at UAB. We are indebted to Dr. G. Yancey Gillespie for scientific advice, to Mary Shirley and Dale Isabelle for administrative assistance, and to Drs. Koen De Clercq and Angela Alexander for custom software that facilitates the analyses of individual HLA class I sequences motifs (SSO probes). The findings and conclusions from this study are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health.
###end p 62
###begin title 63
References
###end title 63
###begin article-title 64
Centralized databases available for describing primary brain tumor incidence, survival, and treatment: Central Brain Tumor Registry of the United States; Surveillance, Epidemiology, and End Results; and National Cancer Data Base.
###end article-title 64
###begin article-title 65
Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994.
###end article-title 65
###begin article-title 66
The WHO classification of tumors of the nervous system.
###end article-title 66
###begin article-title 67
Epidemiology of primary brain tumors: current concepts and review of the literature.
###end article-title 67
###begin article-title 68
Molecular epidemiology of glioblastoma.
###end article-title 68
###begin article-title 69
Genetic pathways to glioblastoma: a population-based study.
###end article-title 69
###begin article-title 70
Malignant gliomas in adults.
###end article-title 70
###begin article-title 71
Ethnicity delineates different genetic pathways in malignant glioma.
###end article-title 71
###begin article-title 72
Central brain tumor registry of the United States.
###end article-title 72
###begin article-title 73
Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium.
###end article-title 73
###begin article-title 74
###xml 25 30 <span type="species:ncbi:9606">human</span>
Gene map of the extended human MHC.
###end article-title 74
###begin article-title 75
Cancer immunology.
###end article-title 75
###begin article-title 76
###xml 41 46 <span type="species:ncbi:9606">human</span>
Association of malignant glioma with the human leukocyte antigen, HLA-A24(9).
###end article-title 76
###begin article-title 77
###xml 75 83 <span type="species:ncbi:9606">patients</span>
Tumor necrosis factor microsatellite polymorphisms in Italian glioblastoma patients.
###end article-title 77
###begin article-title 78
###xml 17 22 <span type="species:ncbi:9606">human</span>
Brain glioma and human leukocyte antigens (HLA)-is there an association.
###end article-title 78
###begin article-title 79
###xml 38 43 <span type="species:ncbi:9606">human</span>
Positive and negative associations of human leukocyte antigen variants with the onset and prognosis of adult glioblastoma multiforme.
###end article-title 79
###begin article-title 80
###xml 21 26 <span type="species:ncbi:9606">human</span>
Associations between human leukocyte antigen type and nasopharyngeal carcinoma in Caucasians in the United States.
###end article-title 80
###begin article-title 81
HLA associations with nasopharyngeal carcinoma in Southern Chinese: a meta-analysis.
###end article-title 81
###begin article-title 82
Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan.
###end article-title 82
###begin article-title 83
Host and viral genetics and risk of cervical cancer: a review.
###end article-title 83
###begin article-title 84
###xml 0 28 <span type="species:ncbi:333760">Human papillomavirus type 16</span>
###xml 81 86 <span type="species:ncbi:9606">women</span>
Human papillomavirus type 16 E6 variants and HLA class II alleles among Japanese women with cervical cancer.
###end article-title 84
###begin article-title 85
###xml 20 43 <span type="species:ncbi:333760">human papillomavirus 16</span>
###xml 60 65 <span type="species:ncbi:9606">human</span>
###xml 135 140 <span type="species:ncbi:9606">women</span>
Association between human papillomavirus 16 E6 variants and human leukocyte antigen class I polymorphism in cervical cancer of Swedish women.
###end article-title 85
###begin article-title 86
HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity.
###end article-title 86
###begin article-title 87
###xml 34 62 <span type="species:ncbi:333760">human papillomavirus type 16</span>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
###xml 169 174 <span type="species:ncbi:9606">human</span>
Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes.
###end article-title 87
###begin article-title 88
###xml 0 23 <span type="species:ncbi:333760">Human papillomavirus 16</span>
###xml 124 129 <span type="species:ncbi:9606">human</span>
Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes.
###end article-title 88
###begin article-title 89
The Upper Midwest Health Study: a case-control study of primary intracranial gliomas in farm and rural residents.
###end article-title 89
###begin article-title 90
Single-nucleotide polymorphisms in selected cytokine genes and risk of adult glioma.
###end article-title 90
###begin article-title 91
Taxonomic hierarchy of HLA class I allele sequences.
###end article-title 91
###begin article-title 92
HLA dictionary 2004: summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and -DQ antigens.
###end article-title 92
###begin article-title 93
###xml 25 37 25 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TERT-CLPTM1L</italic>
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types.
###end article-title 93
###begin article-title 94
###xml 39 42 <span type="species:ncbi:9606">men</span>
Gliomas and farm pesticide exposure in men: the Upper Midwest Health Study.
###end article-title 94
###begin article-title 95
The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense.
###end article-title 95
###begin article-title 96
Unusual selection on the KIR3DL1/S1 natural killer cell receptor in Africans.
###end article-title 96
###begin article-title 97
###xml 35 40 <span type="species:ncbi:9606">human</span>
The Yin and Yang of HLA and KIR in human disease.
###end article-title 97
###begin article-title 98
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
Human leukocyte antigen distribution analysis in North Italian brain Glioma patients: an association with HLA-DRB1*14.
###end article-title 98
###begin article-title 99
###xml 50 55 <span type="species:ncbi:9606">human</span>
Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement.
###end article-title 99
###begin article-title 100
Hide-and-seek in the brain: a role for HLA-G mediating immune privilege for glioma cells.
###end article-title 100
###begin article-title 101
HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo.
###end article-title 101
###begin article-title 102
###xml 25 30 <span type="species:ncbi:9606">human</span>
Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells.
###end article-title 102
###begin article-title 103
Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma.
###end article-title 103
###begin article-title 104
###xml 13 21 <span type="species:ncbi:9606">patients</span>
Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
###end article-title 104
###begin article-title 105
###xml 85 90 <span type="species:ncbi:9606">human</span>
Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.
###end article-title 105
###begin article-title 106
Induction of cytotoxic T lymphocytes specific to malignant glioma using T2 cells pulsed with HLA-A2-restricted interleukin-13 receptor alpha 2 peptide in vitro.
###end article-title 106
###begin article-title 107
###xml 20 25 <span type="species:ncbi:9606">human</span>
Identification of a human leukocyte antigen-A24-restricted T-cell epitope derived from interleukin-13 receptor alpha2 chain, a glioma-associated antigen.
###end article-title 107
###begin article-title 108
###xml 63 68 <span type="species:ncbi:9606">human</span>
VEGF-D is an X-linked/AP-1 regulated putative onco-angiogen in human glioblastoma multiforme.
###end article-title 108
###begin article-title 109
###xml 76 81 <span type="species:ncbi:9606">human</span>
Cancer Genome Atlas Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
###end article-title 109
###begin article-title 110
###xml 34 39 <span type="species:ncbi:9606">human</span>
An integrated genomic analysis of human glioblastoma multiforme.
###end article-title 110
###begin article-title 111
Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy.
###end article-title 111
###begin article-title 112
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IDH1</italic>
###xml 9 13 9 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IDH2</italic>
IDH1 and IDH2 Mutations in gliomas.
###end article-title 112
###begin article-title 113
Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations.
###end article-title 113
###begin article-title 114
High-resolution HLA alleles and haplotypes in the United States population.
###end article-title 114
###begin article-title 115
Natural selection and the diversification of vertebrate immune effectors.
###end article-title 115
###begin article-title 116
Natural selection: The evolution of cancer.
###end article-title 116
###begin article-title 117
Genome-wide association study identifies five susceptibility loci for glioma.
###end article-title 117
###begin article-title 118
###xml 16 22 16 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2B</italic>
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RTEL1</italic>
Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility.
###end article-title 118
###begin article-title 119
Analysis of the distribution of HLA-A alleles in populations from five continents.
###end article-title 119
###begin article-title 120
###xml 20 25 <span type="species:ncbi:9606">human</span>
Molecular typing of human leukocyte antigen and related polymorphisms following whole genome amplification.
###end article-title 120
###begin article-title 121
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 70 73 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Human leukocyte antigen class I genotypes in relation to heterosexual HIV type 1 transmission within discordant couples.
###end article-title 121
###begin article-title 122
Transcriptional regulation of the MHC class I HLA-A11 promoter by the zinc finger protein ZFX.
###end article-title 122
###begin article-title 123
Downregulation of HLA class I gene transcription in choriocarcinoma cells is controlled by the proximal promoter element and can be reversed by CIITA.
###end article-title 123
###begin article-title 124
Synergistic induction of HLA class I expression by RelA and CIITA.
###end article-title 124
###begin p 125
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 125
###begin p 126
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by grants CA128059, CA097257 and CA097247 from the National Cancer Institute. JT is the recipient of an independent scientist award (K02 AI076123) from National Institute of Allergy and Infectious Diseases. The funders had no role in study design, data collection, data analyses, decision to publish, or preparation of this manuscript.
###end p 126

